BR112022024760A2 - Métodos de tratamento do complexo de esclerose tuberosa - Google Patents

Métodos de tratamento do complexo de esclerose tuberosa

Info

Publication number
BR112022024760A2
BR112022024760A2 BR112022024760A BR112022024760A BR112022024760A2 BR 112022024760 A2 BR112022024760 A2 BR 112022024760A2 BR 112022024760 A BR112022024760 A BR 112022024760A BR 112022024760 A BR112022024760 A BR 112022024760A BR 112022024760 A2 BR112022024760 A2 BR 112022024760A2
Authority
BR
Brazil
Prior art keywords
methods
tuberous sclerosis
treatment
sclerosis complex
individual
Prior art date
Application number
BR112022024760A
Other languages
English (en)
Portuguese (pt)
Inventor
Garibaldi George
Original Assignee
Noema Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noema Pharma Ag filed Critical Noema Pharma Ag
Publication of BR112022024760A2 publication Critical patent/BR112022024760A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Fruits And Vegetables (AREA)
BR112022024760A 2020-06-05 2021-06-04 Métodos de tratamento do complexo de esclerose tuberosa BR112022024760A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063035313P 2020-06-05 2020-06-05
PCT/EP2021/065075 WO2021245281A1 (en) 2020-06-05 2021-06-04 Methods of treatment of tuberous sclerosis complex

Publications (1)

Publication Number Publication Date
BR112022024760A2 true BR112022024760A2 (pt) 2023-03-07

Family

ID=76325558

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024760A BR112022024760A2 (pt) 2020-06-05 2021-06-04 Métodos de tratamento do complexo de esclerose tuberosa

Country Status (13)

Country Link
US (3) US11684613B2 (https=)
EP (1) EP4161512A1 (https=)
JP (2) JP2023528895A (https=)
KR (2) KR20230027145A (https=)
CN (1) CN116056701A (https=)
AU (1) AU2021285273A1 (https=)
BR (1) BR112022024760A2 (https=)
CA (1) CA3180794A1 (https=)
CL (1) CL2022003435A1 (https=)
IL (2) IL322310A (https=)
MX (1) MX2022015407A (https=)
PH (1) PH12023550016A1 (https=)
WO (1) WO2021245281A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022024760A2 (pt) * 2020-06-05 2023-03-07 Noema Pharma Ag Métodos de tratamento do complexo de esclerose tuberosa
EP4658268A1 (en) * 2023-02-02 2025-12-10 Noema Pharma AG Methods of treatment of dravet syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80888C2 (en) 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
NZ551253A (en) 2004-06-01 2010-07-30 Hoffmann La Roche Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists
MY148217A (en) * 2006-12-21 2013-03-29 Hoffmann La Roche Polymorphs of a mglur5 receptor antagonist
US8211882B2 (en) 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120039999A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
BR112022024760A2 (pt) * 2020-06-05 2023-03-07 Noema Pharma Ag Métodos de tratamento do complexo de esclerose tuberosa

Also Published As

Publication number Publication date
AU2021285273A1 (en) 2023-01-19
CA3180794A1 (en) 2021-12-09
IL298709A (en) 2023-02-01
US20230100520A1 (en) 2023-03-30
CN116056701A (zh) 2023-05-02
JP2025122066A (ja) 2025-08-20
PH12023550016A1 (en) 2024-03-11
US20230277513A1 (en) 2023-09-07
US11998535B2 (en) 2024-06-04
JP2023528895A (ja) 2023-07-06
KR20250116184A (ko) 2025-07-31
US20250099445A1 (en) 2025-03-27
US11684613B2 (en) 2023-06-27
IL322310A (en) 2025-09-01
EP4161512A1 (en) 2023-04-12
MX2022015407A (es) 2023-05-16
WO2021245281A1 (en) 2021-12-09
CL2022003435A1 (es) 2023-10-20
KR20230027145A (ko) 2023-02-27

Similar Documents

Publication Publication Date Title
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
MX2021005087A (es) Compuestos de formula i para usarse en el tratamiento de infecciones por virus arenaviridae y coronaviridae.
BR112022024760A2 (pt) Métodos de tratamento do complexo de esclerose tuberosa
PH12019501222A1 (en) Cyclic dinucleotides as sting (stimulator of interferon genes) agonists
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
PH12017502363A1 (en) Brk inhibitory compound
MX2022001690A (es) Compuestos deuterados para usarse en el tratamiento del cancer.
BR112018075947A2 (pt) composições de revestimento
BR112018006445A2 (pt) métodos para tratar distrofia muscular
BR112016000975A8 (pt) esteróides neuroativos, composições os compreendendo e uso dos mesmos
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
CL2019002220A1 (es) Gasotransmisor electroquímico que genera composiciones y métodos de uso de los mismos y apósitos y sistemas de tratamiento que incorpora los mismos.
BR112019006113A2 (pt) métodos de tratamento de distúrbios mitocondriais e metabólicos
ECSP20081995A (es) Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
UY36868A (es) Composiciones para tratamiento de enfermedades mediadas por interleuquina 5 (il-5)
ECSP22026478A (es) Inhibidor de diacilglicerol aciltransferasa 2
SG11201811536PA (en) Composition for removing sulfur-containing compound
BR112021018924A2 (pt) Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento
UA117673C2 (uk) Поліміксини, композиція, спосіб одержання і спосіб застосування (варіанти)
BR112023019622A2 (pt) Preparação contendo composto de peptídeo cíclico e método para a produção do mesmo
BRPI0511569A (pt) composições e métodos para o tratamento de distúrbio disfórico pré-menstrual
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
PH12021553164A1 (en) Biofilm disruption
EA201891808A1 (ru) Трис-амидные соединения и композиции, содержащие их
MX2023004955A (es) Compuestos de aminotiazol deuterados como compuestos antiviricos.